DocWire News Editors

DocwireNews

Chicago&mdash;Androgen signaling is not entirely suppressed with androgen deprivation therapy (ADT) with GnRH analogs. Abiraterone acetate plus prednisone added to ADT decreases blood and intramural levels of testosterone by &ge;1 log, and, in pre-radical prostatectomy trials, resulted in greater pathologic responses compared with ADT alone.Given the long history of prostate cancer and the resources required for phase 3 trials, study designs that aim to rapidly assess therapies are critical, according to Karen A. Autio, MD, and colleagues who used a novel end point (undetectable prostate-specific antigen [PSA] with testosterone recovery) to test the hypothesis that abiraterone acetate in combination with prednisone administered in the &ldquo;rising PSA state following radical prostatectomy, a low volume but potentially lethal setting, could eliminate all disease, a prerequisite to cure.&rdquo;The researchers reported results of the study during a poster session at the ASCO 2018 Annual Meeting in a poster titled Phase 2, Randomized, 3-Arm Study of Abiraterone Acetate and Prednisone (AAP), AAP plus Degarelix (AAP+D), and Degarelix (D) Alone for Patients (pts) with Biochemically Recurrent Prostate Cancer (PC) Following Radical Prostatectomy (RP).Patients who underwent radical prostatectomy &plusmn; salvage radiotherapy with a rising PSA &ge;1.0 ng/mL, PSA doubling time &le;9 months, no metastases on computed tomography/bone scan, and testosterone &ge;150 ng/mL were eligible to participate in the study. Prior ADT &le;8 months was allowed.Patients were randomized in a 1:1 ratio to receive 1000 mg abiraterone acetate plus 5 mg prednisone once daily (group 1) abiraterone acetate plus prednisone plus monthly degarelix (group 2), or monthly degarelix (group 3) for 8 months, followed by cessation of therapy. The primary end point of interest was PSA0 with testosterone &gt;150 at 18 months; a secondary end point was PSA0 at 8 months.A total of 120 patients were treated. Of those, 113 were evaluable for the primary end point; seven had PSA0 at 18 months without testosterone recovery. At 8 months, there was no difference in PSA0 in group 1 compared with group 2 or group 3. Overall, 11.5% of patients achieved the primary end point with no difference between groups. Testosterone recovery was shortest in group 1 compared with group 3.In summary, the researchers said, &ldquo;Although no difference between treatment groups was identified by the primary end point (PSA0 + testosterone recovery), these results set a benchmark for future trials that 10-15% of patients can achieve this outcome. Given the survival benefit of abiraterone acetate plus prednisone in non-castrate metastatic prostate cancer, a longer duration of androgen suppression may yield greater benefit. In addition to novel systemic therapies, use of positive emission tomography directed imaging to identify and target micro-mets with focal therapies may enhance the likelihood of eliminating disease in this setting.&rdquo;Clinical trial information: NCT01751451Source: Autio KA, Antonarakis ES, Mayer TM, et al. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP + P), and degarelix (D) alone for patients (pts) with biochemically recurrent prostate cancer (PC) following radical prostatectomy (RP). Abstract of a poster presented at the American Society of Clinical Oncology 2018 Annual Meeting, June 2, 2018, Chicago, Illinois.

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Longer Duration of Androgen Suppression Examined in Phase 2 Study

ASCO 2018

Chicago—Androgen signaling is not entirely suppressed with androgen deprivation therapy (ADT) with GnRH analogs. Abiraterone acetate plus prednisone added to ADT decreases ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe